VKORC1 - The Warfarin Sensitivity Gene
VKORC111 Vitamin K Epoxide Reductase Complex Subunit 1 encodes the target enzyme
of warfarin. While CYP2C9 determines how quickly you metabolize warfarin, VKORC1
determines how sensitive your body is to it. Together, these two genes account for
about 40-50% of the variability in warfarin dose requirements between individuals,
with VKORC1 alone contributing approximately 25 percent22 approximately 25 percent
Rieder MJ et al. PNAS, 2005.
The Mechanism
The -1639G>A variant33 rs9923231 is in the promoter region of VKORC1 and affects
gene expression. The T allele reduces VKORC1 transcription by approximately
44% compared to the C allele44 44% compared to the C allele
measured by dual luciferase assay, producing
less target enzyme. Since warfarin works by inhibiting VKORC1, having less enzyme
means less warfarin is needed to achieve the same anticoagulant effect. This is why
T allele carriers are "sensitive" to warfarin - they need lower doses.
Warfarin Dose Ranges
The impact on dosing is substantial: - CC genotype: typically requires 5-7mg daily - TC genotype: typically requires 3-4mg daily - TT genotype: typically requires 1.5-2.5mg daily
These are rough ranges - actual doses also depend on CYP2C9 genotype, age, weight, interacting medications, and dietary vitamin K intake.
The Pharmacogenomic Success Story
Warfarin pharmacogenomics is one of the most validated applications of personalized medicine.
Practical Implications
If you carry the T allele (AG or AA), you will need lower warfarin doses than average if ever prescribed this medication. This information should be in your medical record. While direct oral anticoagulants55 DOACs: newer blood thinners like apixaban and rivaroxaban that do not require genetic dose adjustment have replaced warfarin in many scenarios, warfarin remains the standard for mechanical heart valves and certain other conditions.